A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Recruiting now · Phase 1/Phase 2
Conditions studied: B-cell Acute Lymphoblastic Leukemia
In brief
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
Key facts
- Study ID
- NCT05667506
- Run by
- Juventas Cell Therapy Ltd.
- People needed
- 47
- Starts
- 2023-02-07
- Expected to finish
- 2027-05-30
- Last updated by the study team
- 2025-08-12
Who can join
Age: 3 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Affiliated Hospital of Xuzhou Medical University — Xuzhou, Jiangsu, China (enrolling)
- The First Affilicated Hospital of Nanchang University — Nanchang, Jiangxi, China (enrolling)
- Institute of Hematology & Blood Diseases Hospital — Tianjin, Tianjin Municipality, China (enrolling)
- Children's Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (enrolling)
- Guangzhou Women and Children's Medical Center — Guangzhou, Guangdong, China (enrolling)
- Children's Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)
- Union Hospital Tongji Medical College Huazhong University of Science of Technology — Wuhan, Hubei, China
- Nanfang Hospital — Guangzhou, Guangdong, China
- The Second Hospital of Anhui Medical University — Hefei, Anhui, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.